346 related articles for article (PubMed ID: 8523050)
1. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
7. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
[TBL] [Abstract][Full Text] [Related]
10. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Schmidinger M; Budinsky AC; Wenzel C; Locker GJ; Pluschnig U; Brodowicz T; Kubista E; Maca S; Zabernigg A; Ilsinger P; Seewann L; Hojas S; Blach M; Zielinski CC; Steger GG
Cancer Chemother Pharmacol; 2001; 47(1):57-62. PubMed ID: 11221963
[TBL] [Abstract][Full Text] [Related]
12. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Vici P; Belli F; Di Lauro L; Amodio A; Conti F; Foggi P; Gionfra T; Morelli MF; Botti C; Ferraironi A; Lopez M
Oncology; 2001; 60(1):60-5. PubMed ID: 11150910
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel administered on a weekly basis for metastatic breast cancer.
Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Valero V
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Van Vaerenbergh W; Paridaens R; Thomas J; Wildiers J; Van Oosterom A
Acta Clin Belg; 1998 Aug; 53(4):264-9. PubMed ID: 9795447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]